Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 5385102, 8 pages
https://doi.org/10.1155/2017/5385102
Research Article

Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients

1Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland
2Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland
3Institute of Statistics and Demography, Warsaw School of Economics, Warsaw, Poland

Correspondence should be addressed to Joanna Bartosińska; moc.liamg@iksnisotrabj

Received 13 May 2017; Accepted 6 August 2017; Published 17 October 2017

Academic Editor: Juarez A. S. Quaresma

Copyright © 2017 Joanna Bartosińska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. C. Coates, O. FitzGerald, P. S. Helliwell, and C. Paul, “Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?” Seminars in Arthritis and Rheumatism, vol. 46, no. 3, pp. 291–304, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Zhang, J. C. Schwartz, X. Guo et al., “Structural and functional analysis of the costimulatory receptor programmed death-1,” Immunity, vol. 20, no. 3, pp. 337–347, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Chen, N. Pang, R. Du et al., “Elevated expression of programmed death-1 and programmed death ligand-1 negatively regulates immune response against cervical cancer cells,” Mediators of Inflammation, vol. 2016, Article ID 6891482, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Dulos, G. J. Carven, S. J. van Boxtel et al., “PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer,” Journal of Immunotherapy, vol. 35, no. 2, pp. 169–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Coimbra, A. Figueiredo, E. Castro, P. Rocha-Pereira, and A. Santos-Silva, “The roles of cells and cytokines in the pathogenesis of psoriasis,” International Journal of Dermatology, vol. 51, no. 4, pp. 389–395, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Vičić, S. Peternel, E. Simonić et al., “Cytotoxic T lymphocytes as a potential brake of keratinocyte proliferation in psoriasis,” Medical Hypotheses, vol. 87, no. 2, pp. 66–68, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Sigmundsdóttir, J. E. Gudjónsson, I. Jónsdóttir, B. R. Lúdvíksson, and H. Valdimarsson, “The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease,” Clinical and Experimental Immunology, vol. 126, no. 2, pp. 365–369, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. W. M. Kohlmann, W. Urban, W. Sterry, and J. Foerster, “Correlation of psoriasis activity with abundance of CD25+CD8+ T cells: conditions for cloning T cells from psoriatic plaques,” Experimental Dermatology, vol. 13, no. 10, pp. 607–612, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Ferenczi, L. Burack, M. Pope, J. G. Krueger, and L. M. Austin, “CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry,” Journal of Autoimmunity, vol. 14, no. 1, pp. 63–78, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Porto Ferreira, A. Gomes da Silva, C. J. Martins, and A. M. Da-Cruz, “CD25+CD8+, CLA+CD4+, CD11a+ CD4+, and CD11a+ CD8+ T cell counts are elevated in the blood of Brazilian patients with chronic plaque psoriasis,” Actas Dermo-Sifiliográficas, vol. 102, no. 5, pp. 388–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. F. Santamaría-Babi, “CLA+ T cells in cutaneous disease,” European Journal of Dermatology, vol. 14, no. 1, pp. 13–18, 2004. View at Google Scholar
  12. Y. Teraki, A. Miyake, R. Takebayashi, and T. Shiohara, “Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris,” Clinical and Experimental Dermatology, vol. 29, no. 6, pp. 658–663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. S. Kim, J. H. Je, S. H. Kim et al., “Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis,” Archives of Dermatological Research, vol. 307, no. 6, pp. 531–538, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Peled, M. Strazza, I. Azoulay-Alfaguter, G. J. Silverman, J. U. Scher, and A. Mor, “Analysis of programmed death-1 in patients with psoriatic arthritis,” Inflammation, vol. 38, no. 4, pp. 1573–1579, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Shin, D. S. Kim, S. H. Kim et al., “Decreased PD-1 positive blood follicular helper T cells in patients with psoriasis,” Archives of Dermatological Research, vol. 308, no. 8, pp. 593–599, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wang, L. Wang, H. Yang, W. Yuan, J. Ren, and Y. Bai, “Activated circulating T follicular helper cells are associated with disease severity in patients with psoriasis,” Journal of Immunology Research, vol. 2016, Article ID 7346030, 13 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Niu, Z. Song, X. Yang, Z. Zhai, H. Zhong, and F. Hao, “Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 9, pp. 1791–1796, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Çetinözman, P. M. Jansen, and R. Willemze, “Expression of programmed death-1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma,” The British Journal of Dermatology, vol. 171, no. 3, pp. 499–504, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Okazaki and T. Honjo, “The PD-1-PD-L pathway in immunological tolerance,” Trends in Immunology, vol. 27, pp. 195–201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Imai, N. Ayithan, X. Wu, Y. Yuan, L. Wang, and S. T. Hwang, “Cutting edge: PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate γδ-low T cells,” Journal of Immunology, vol. 195, no. 2, pp. 421–425, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. P. L. Chia and T. John, “Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC),” Journal of Immunotherapy, vol. 39, no. 5, pp. 202–204, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Matsumura, M. Ohtsuka, N. Kikuchi, and T. Yamamoto, “Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma,” Acta Dermato-Venereologica, vol. 96, no. 2, pp. 259-260, 2016. View at Publisher · View at Google Scholar · View at Scopus